Real-world Daptomycin Use in Chinese ICUs
Real-world Daptomycin Use in Chinese ICUs
NCT ID: NCT03588637 Phase: Status: COMPLETED Enrollment: 200 Completion: 2021-12-30
Conditions
Daptomycin, Real-world Study, Intensive Care Unit
Interventions
No intervention
Summary
Analyze the effectiveness and safety of Daptomycin(Jiangsu Hengrui Medicine Co., Ltd) in Gram-positive infections in Chinese Intensive Care Units by using the real-world data platform, https://rws.scccmqc.com. Patients who received at least one dose of Daptomycin between 2016 to 2021 are eligible.
Primary Outcome
mortality